Clinical trials: Psychosis Prodrome
Prodromal Schizophrenia
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia…
- Trial name
- NCT05052853
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- China Medical University Hospital
Schizophrenia, Psychosis
Aripiprazole Treatment of Prodromal Patients
We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.
- Trial name
- NCT00237874
- Testing
- Aripiprazole
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Yale University
Prodromal Schizophrenia
"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
Schizophrenia is a severe mental disorder associated with significant impairments in affective, cognitive and social functioning.
- Trial name
- ESPRIT-B1 (NCT03149107)
- Testing
- N-Acetylcysteine, IPPI (Integrated Preventive Psychological Intervention), PSM (Psychological stress management)
- Where
- 10 sites in Germany
- Volunteers
- 48 people
- Sponsor
- University Hospital, Bonn
Prodromal Schizophrenia, Prodromal Psychosis
Aripiprazole Treatment of the Prodrome
The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects.
- Trial name
- NCT00169949
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Psychotic Disorders, Personality Disorders
The Staged Treatment in Early Psychosis Study
A sequential multistage randomised clinical trial (SMART) to produce evidence to guide a step-wise clinical approach for the treatment of ultra high risk patients and reduction of risk for psychosis and other deleterious clinical…
- Conditions
- Psychotic Disorders, Personality Disorders, Clinical High Risk
- Trial name
- STEP (NCT02751632)
- Testing
- Support and Problem Solving Therapy, Cognitive Behavioural Case Management, Fluoxetine
- Where
- 5 sites in Australia
- Volunteers
- 342 people
- Sponsor
- Orygen